Anthropic has acquired Mithril Medicine, a one-person startup developing treatments for two rare types of muscular dystrophy. The company also published early results from research partnerships with six drug development companies, including Bristol Myers Squibb and Invita.
Details of the Mithril Medicine acquisition and research partners
One-person biotech company manages 11 labs via Claude
Impressive results in document review and T-cell design
Moving toward clinical trials and launching the Claude Science platform
Frequently asked questions
Details of the Mithril Medicine acquisition and research partners
AI firm Anthropic has acquired Mithril Medicine, a single-person startup working on treatments for two rare types of muscular dystrophy. On October 27, Anthropic also published preliminary results from months of research partnerships with six drug development firms—including Bristol Myers Squibb, Invita, BigHat Biosciences, Divergence Labs, Generate Biomedicines, and The Column Group. According to Becker’s Hospital Review, most of this work remains in the preclinical phase, meaning none of the candidate drug compounds have been tested on humans yet, while financial terms of the deal were not disclosed per Benzinga.
One-person biotech company manages 11 labs via Claude
Mithril founder Cody Tranbarger relied on the Claude AI model to manage contracts, logistics, and scientific experiments across 11 external laboratories. Anthropic stated that he successfully moved a potential treatment from a mere concept to promising results in mice in under 18 months. The program targets LAMA2-related congenital muscular dystrophy and alpha-dystroglycanopathy. Mithril has designed over 100 bispecific antibodies currently undergoing cell-based testing, aiming to name official drug candidates for both diseases in 2027, according to Unite.AI. Anthropic noted that the mouse data does not yet prove whether the treatments are safe or effective in human patients, but Tranbarger continues his work within Anthropic, which projected that human trials could begin by late 2028 if the findings hold up.
Impressive results in document review and T-cell design
At Invita, the Claude model reviewed 1,061 pages of pharmaceutical manufacturing documentation and managed to catch all 11 issues flagged by human reviewers, plus 7 additional issues they missed, cutting human review time by 89% according to the Becker’s report. Invita explained that the work encompassed good manufacturing practice records and the drafting of large portions of an Investigational New Drug application while experts continued to audit the outputs. Meanwhile, scientists at Generate Biomedicines used the Claude Code tool to design a chimeric antigen receptor T-cell therapy component roughly 70% shorter than the standard version, which produced about 10 times the number of receptors on immune cells in lab tests. BigHat Biosciences also tested roughly 1.01×10¹⁰ antibody variants suggested by Claude over roughly 10 weeks.
Moving toward clinical trials and launching the Claude Science platform
Bristol Myers Squibb is using the Claude model to review clinical trial plans for an early-stage drug and estimate the success probabilities of those trials, with the two companies planning to expand this collaboration in 2027. Anthropic also launched the Claude Science research platform equipped with computing credits according to Silicon Report. Michael Bourdenad, head of early clinical development for hematology, oncology, and cell therapy at Bristol Myers Squibb, said: “With a single prompt, Claude generated a robust initial analysis that helped guide our evaluation of various development options, work that would have taken several days to complete.”
Frequently asked questions
Question: How did the founder of Mithril Medicine manage to develop a treatment single-handedly?
Answer: Cody Tranbarger used the Claude model to manage contracts, logistics, and experiments across 11 external labs to reach promising mouse results in under 18 months.
Question: What results did Claude achieve with pharmaceutical company Invita?
Answer: It reviewed 1,061 pages of manufacturing documentation, discovered 11 errors spotted by humans plus 7 errors they overlooked, and cut review time by 89%.
Question: When could human clinical trials for Mithril’s treatments begin?
Answer: The company aims to name drug candidates in 2027, and human trials could begin in late 2028 pending successful preliminary testing.
